BCAT2: A Protein with Potential Drug Targets and Cancer Biomarkers

Target Name: BCAT2

NCBI ID: G587

BCAT2

BCAT2: A Protein with Potential Drug Targets and Cancer Biomarkers

Branched chain aminotransferase 2 (BCAT2) is a protein that is expressed in the liver and other tissues of the body. It is a key enzyme in the citric acid cycle, also known as the Krebs cycle or TCA cycle, which is a central metabolic pathway that generates energy in the form of ATP from food molecules. BCAT2 is involved in the transfer of amino acids from the citric acid cycle to the cytosol, where they can be used to synthesize other molecules, such as aromatic amino acids, which are important for the synthesis of aromatic proteins.

Despite its importance in the cell, BCAT2 is not well understood, and its function and significance are still the subject of research. However, there is evidence to suggest that it may be a drug target or biomarker for a variety of diseases.

One potential drug target for BCAT2 is the treatment of metabolic disorders. Metabolic disorders are a group of conditions that are characterized by abnormalities in the metabolism of energy by the body. These disorders can be caused by a variety of factors, including genetic mutations, obesity , and diabetes. Some of the most common metabolic disorders include diabetes, hyperlipidemia (elevated levels of fat in the blood), and fatty liver disease.

BCAT2 is involved in the citric acid cycle, which is a key step in the metabolism of energy. It is possible that drugs that target BCAT2 may be effective in treating metabolic disorders by altering the metabolism of energy in the body. For example, some studies have suggested that inhibiting BCAT2 may be effective in reducing the levels of fat in the liver, which is a common feature of metabolic disorders.

Another potential drug target for BCAT2 is the treatment of certain types of cancer. BCAT2 is involved in the synthesis of aromatic amino acids, which are important for the development and progression of certain types of cancer. Therefore, inhibiting BCAT2 may be effective in inhibiting the growth and progression of these cancers.

Additionally, some studies have suggested that BCAT2 may be a potential biomarker for certain types of cancer. The cytosol is the part of the cell where BCAT2 is expressed, and it is possible that the levels of BCAT2 in the cytosol may be an indicator of the presence of certain types of cancer. Therefore, measuring the levels of BCAT2 in the cytosol may be a promising way to diagnose or predict the type of cancer a person has.

In conclusion, BCAT2 is a protein that is expressed in the liver and other tissues of the body. While its full function and significance are still the subject of research, there is evidence to suggest that it may be a drug target or biomarker for a variety of diseases, including metabolic disorders and certain types of cancer. Further research is needed to fully understand its role in the body and its potential as a therapeutic target.

Protein Name: Branched Chain Amino Acid Transaminase 2

Functions: Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine (PubMed:8702755, PubMed:25653144, PubMed:17050531). May also function as a transporter of branched chain alpha-keto acids (By similarity)

The "BCAT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BCAT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets